SCHEMBL5459783

SCHEMBL5459783

NC(=O)c1c(NC(=O)C2CC2)sc2ccc(N)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.48
MAPK10 P53779 2/20 0.46
GFER P55789 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
AURKA O14965 1/20 0.44
AURKB Q96GD4 1/20 0.44
MAPT P10636 3/20 0.43
HTT P42858 1/20 0.40
TNIK Q9UKE5 3/20 0.40
MAPK1 P28482 2/20 0.40
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5467348 0.86 FLT3 (0.47) FLT3MAPK10GFERMEN1KMT2A
SCHEMBL14361160 0.83 FLT3 (0.44) FLT3MAPK10GFERMEN1KMT2A
SCHEMBL5460557 0.83 FLT3 (0.51) FLT3MAPK10MEN1KMT2ANPC1
SCHEMBL5448452 0.82 NAMPT (0.49) FLT3MAPK10MEN1KMT2ANPC1
SCHEMBL5450627 0.80 AURKA (0.50) FLT3GFERMEN1KMT2ANPC1
SCHEMBL5466117 0.80 FLT3 (0.48) FLT3MAPK10GFERKMT2ANPC1
SCHEMBL5450964 0.80 FLT3 (0.48) FLT3MAPK10GFERAURKAAURKB
SCHEMBL5460352 0.79 AURKA (0.43) FLT3MAPK10MEN1KMT2ANPC1
SCHEMBL5453459 0.79 AURKA (0.43) FLT3MAPK10MEN1KMT2ANPC1
SCHEMBL17611488 0.78 FLT3 (0.46) FLT3MAPK10GFERMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885MAPK10 1060/4885GFER 4508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.